Operator
Good morning, and welcome to the VYNE Therapeutics conference call to discuss the first-quarter 2021 financial results and update. [Operator instructions] Please be advised that this call is being recorded at the company s request. I will now turn the call over to Michael Wood at LifeSci Advisors. Please go ahead.
Michael Wood
LifeSci Advisors Managing Director
Good morning, everyone, and thank you for joining us. Before we begin formal remarks, let me remind you that some of the information in the press release issued this morning and on this conference call contain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict including statements, forecasts and observations regarding future financial operating performance, impacts of the COVID-19 pandemic online and observations regarding ongoing operating expenses and net revenue. These statements include observations associated with commercialization of AMZEEQ and ZIL